FloodLAMP archive category

Regulatory

The Regulatory category covers the policy and regulatory environment around COVID-19 testing, including FloodLAMP's own FDA submissions and correspondence, the surveillance framework it operated under, and related commentary on open-access diagnostics and pandemic preparedness.

Download the combined markdown of all converted archive files in this category

Subcategories

Selected FDA EUA Documents (2 files)

A reference set of EUA documents FloodLAMP studied during development, including comparable authorized tests and instructive examples of the FDA's authorization model.

Open the fuller context and commentary Download the combined markdown of all converted archive files in this subcategory

FDA Policy (48 files)

The evolving FDA policy framework for COVID-19 testing, including guidance versions, templates, screening policy, pooling policy, and transition-era materials.

Open the fuller context and commentary Download the combined markdown of all converted archive files in this subcategory
2020-02-29_FDA Guidance - COVID IVD Test Developers v1.md 2020-03-16_FDA Guidance - COVID IVD Test Developers v2.md 2020-03-31_FDA Website - EUA for Molecular Diagnostic Tests.md 2020-04-28_FDA Website - Umbrella EUA for Independently Validated Serology Tests.md 2020-05-04_FDA Guidance - COVID IVD Test Developers v3.md 2020-05-11_FDA Guidance - COVID IVD Test Developers v4.md 2020-05-29_FDA Template - Home Specimen Collection Molecular Diagnostic Template.md 2020-07-21_FDA Letter - Serology IVD Umbrella Revocation.md 2020-07-28_FDA Template - Molecular Diagnostic Template for Commercial Manufacturers.md 2020-07-29_FDA Template - For Manufacturers of Molecular and Antigen Diagnostic COVID-19 Tests for Non-Laboratory Use.md 2020-08-04_FDA Policy IVD - Sensitivity and Specificity Study Outline ABBREVIATED STUDY.md 2020-08-04_FDA Policy IVD - Sensitivity and Specificity Study Outline FULL STUDY.md 2020-08-24_FDA Policy IVD - Pooled Sample Testing and Screening Testing for COVID-19.md 2020-10-26_FDA Template - Antigen Template for Test Developers.md 2021-03-13_FDA Fact Sheet - Screening for COVID-19 Deciding Which Test to Use When Establishing Testing Programs.md 2021-03-16_FDA Template - Supplemental Template for Developers of Molecular and Antigen Diagnostic COVID-19 Tests for Screening with Serial Testing.md 2021-03-16_FDA Website - FDA takes steps to streamline path for COVID-19 screening tools.md 2021-04-20_FDA Fact Sheet - Sample Updated Fact Sheet for Health Care Providers.md 2021-04-20_FDA Fact Sheet - Sample Updated Fact Sheet for Patients.md 2021-04-20_FDA Letter - Amendment Letter.md 2021-04-20_FDA Website - Pooling and Serial Testing Amendment.md 2021-09-23_FDA Letter - Viral Mutation Revision Letter.md 2021-09-23_FDA Website - Revision Concerning Viral Mutations.md 2021-10-06_FDA Template - For Developers of Molecular Diagnostic Tests.md 2021-10-25_FDA Template - Supplemental Template for Developers of Molecular and Antigen Diagnostic COVID-19 Tests for Screening with Serial Testing.md 2021-11-09_FDA Template - For Developers of Molecular and Antigen Diagnostic COVID-19 Tests for Home Use.md 2021-11-15_FDA Fact Sheet - Fact Sheet for Health Care Providers Template.md 2021-11-15_FDA Fact Sheet - Fact Sheet for Healthcare Providers.md 2021-11-15_FDA Fact Sheet - Fact Sheet for Patients Template.md 2021-11-15_FDA Fact Sheet - Fact Sheet for Patients.md 2021-11-15_FDA Fact Sheet - Test Summary Template.md 2021-11-15_FDA Guidance - COVID IVD Test Developers v5.md 2021-11-15_FDA Letter - EUA Letter of Authorization.md 2021-11-15_FDA Letter - Laboratories Who Have Developed a Molecular-Based Test.md 2021-11-15_FDA Website - Umbrella EUA.md 2022-09-27_FDA Guidance - COVID IVD Test Developers v6.md 2022-11-01_FDA Letter - Repeat Testing Revision Letter.md 2022-11-01_FDA Website - Antigen EUA Revisions for Serial Repeat Testing.md 2022-11-17_FDA Website - At Home COVID-19 Antigen Tests-Take Steps.md 2023-01-12_FDA Guidance - COVID IVD Test Developers v7.md 2023-03-24_FDA Website - Transition Plan for Medical Devices.md 2023-03-27_FDA Guidance - Transition Plan for Medical Devices Issued EUAs.md 2023-03-27_FDA Guidance - Transition Plan for Medical Devices That Fall Within Enforcement Policies.md 2023-04-18_FDA Website - Webinar on Guidances on COVID-19 Transition Plans.md 2023-09-23_FDA Response Letter - To Compliant regarding FDA Reference Panel from Dec 2020.md 2023-11-08_FDA Website - In Vitro Diagnostics EUAs.md _context-commentary_regulatory-fda-policy.md FDA SARS-CoV-2 Reference Panel Comparative Data - Complied by Matt McFarlane.md

FloodLAMP FDA Submissions (16 files)

FloodLAMP's own EUA submissions and Instructions for Use documents, including for the primary test utilized in FloodLAMP's real-world pilot programs ("QuickColor" extraction-free colorimetric LAMP test) and for a companion "EasyPCR" test run from the same inactivated sample and utilizing the SalivaDirect primers and probes. Also addressed is the broader open-source protocol regulatory strategy.

Open the fuller context and commentary Download the combined markdown of all converted archive files in this subcategory

FloodLAMP FDA Correspondence (13 files)

The direct written record of FloodLAMP's interactions with the FDA, including pre-EUA contacts, review communications, deficiency letters, and closure of the submission effort.

Open the fuller context and commentary Download the combined markdown of all converted archive files in this subcategory

IRB and Clinical Study Materials (4 files)

Protocol and consent materials for the clinical-study path FloodLAMP prepared but never carried through, plus commentary on the cost and friction of the process.

Open the fuller context and commentary Download the combined markdown of all converted archive files in this subcategory

Laboratory-Developed Tests (13 files)

Background on the LDT regulatory pathway and how it intersected with FDA policy, commercial IVDs, and the open-EUA ideas that mattered to FloodLAMP.

Open the fuller context and commentary Download the combined markdown of all converted archive files in this subcategory

Open EUAs (6 files)

Materials on the open-EUA concept that sat at the center of FloodLAMP's regulatory strategy: open protocols, open supply chains, and shared access to authorization.

Open the fuller context and commentary Download the combined markdown of all converted archive files in this subcategory

Regulatory Articles and Reports (5 files)

Broader third-party reports, proposals, and retrospective analyses that help place FloodLAMP's regulatory experience in a larger pandemic-policy context.

Open the fuller context and commentary Download the combined markdown of all converted archive files in this subcategory

Surveillance Testing (15 files)

The regulatory gray-zone framework FloodLAMP ultimately operated under in practice, including how non-diagnostic surveillance was explained, justified, and limited.

Open the fuller context and commentary Download the combined markdown of all converted archive files in this subcategory